BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18930653)

  • 1. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
    Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The design, synthesis and anticancer activity of 4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS].
    Cao X; You QD; Li ZY; Guo QL; Yang Y; Shang J; Yan M; Chen JW; Chen ML
    Yao Xue Xue Bao; 2009 Mar; 44(3):288-95. PubMed ID: 19449526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase.
    Cao X; You QD; Li ZY; Guo QL; Shang J; Yan M; Chern JW; Chen ML
    Bioorg Med Chem; 2008 Jun; 16(11):5890-8. PubMed ID: 18485715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
    Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
    J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases.
    Boschelli DH; Wang YD; Johnson S; Wu B; Ye F; Barrios Sosa AC; Golas JM; Boschelli F
    J Med Chem; 2004 Mar; 47(7):1599-601. PubMed ID: 15027848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
    Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
    Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
    Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
    Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
    Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
    Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.
    Zhang N; Wu B; Powell D; Wissner A; Floyd MB; Kovacs ED; Toral-Barza L; Kohler C
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2825-8. PubMed ID: 11133101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.
    Boschelli DH; Wang YD; Ye F; Wu B; Zhang N; Dutia M; Powell DW; Wissner A; Arndt K; Weber JM; Boschelli F
    J Med Chem; 2001 Mar; 44(5):822-33. PubMed ID: 11262092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety.
    Li S; Huang Q; Liu Y; Zhang X; Liu S; He C; Gong P
    Eur J Med Chem; 2013 Jun; 64():62-73. PubMed ID: 23644189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
    J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
    Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
    Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.